Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00274924 · OUTCOME

2-year Progression-Free Survival (PFS)

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma · Source last updated 2023-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
probability
Interval / dispersion
90% Confidence Interval
Time frame
Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.

What was measured

2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS.

Groups in this outcome

Group I (PET Negative)

Eligible and treated patients who were PET negative after 3 cycles of R-CHOP received 2 more cycles of R-CHOP (6 cycles in total).

Group II (PET Positive)

Eligible and treated patients who were PET positive after 3 cycles of R-CHOP received 4 cycles of R-ICE.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group I (PET Negative)61
Group II (PET Positive)13

Reported measurements

Source class 1
Values in probability · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Group I (PET Negative)0.76Not reported0.650.84Not reported
Group II (PET Positive)0.42Not reported0.190.63Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.65
        upper Limit
        0.84
        value
        0.76
      2. group Id
        OG001
        lower Limit
        0.19
        upper Limit
        0.63
        value
        0.42
denoms
  1. counts
    1. group Id
      OG000
      value
      61
    2. group Id
      OG001
      value
      13
    units
    Participants
description
2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS.
dispersion Type
90% Confidence Interval
groups
  1. description
    Eligible and treated patients who were PET negative after 3 cycles of R-CHOP received 2 more cycles of R-CHOP (6 cycles in total).
    id
    OG000
    title
    Group I (PET Negative)
  2. description
    Eligible and treated patients who were PET positive after 3 cycles of R-CHOP received 4 cycles of R-ICE.
    id
    OG001
    title
    Group II (PET Positive)
param Type
NUMBER
reporting Status
POSTED
time Frame
Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.
title
2-year Progression-Free Survival (PFS)
type
PRIMARY
unit Of Measure
probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice